- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting KRAS in PDAC: A New Way to Cure It?
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 20, Pages 4982
Publisher
MDPI AG
Online
2022-10-12
DOI
10.3390/cancers14204982
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid‑based antisense: A potential new drug candidate for pancreatic cancer
- (2022) Ayelet Shai et al. Oncology Letters
- Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
- (2022) Jiaxin Zhang et al. Frontiers in Pharmacology
- Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer
- (2022) Masahiro Itonaga et al. Cancers
- KRAS mutation allele frequency threshold alters prognosis in right‐sided resected pancreatic cancer
- (2022) David Nauheim et al. JOURNAL OF SURGICAL ONCOLOGY
- KRAS is vulnerable to reversible switch-II pocket engagement in cells
- (2022) James D. Vasta et al. Nature Chemical Biology
- Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
- (2022) Muhammad R. Haque et al. Microsystems & Nanoengineering
- Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer
- (2022) Zhenchong Li et al. Journal of Oncology
- Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
- (2022) Pablo J. Dopico et al. Biosensors-Basel
- Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
- (2022) Winifred Lo et al. CURRENT OPINION IN GASTROENTEROLOGY
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation
- (2021) Noritaka Tanaka et al. Cancer Discovery
- Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling
- (2021) Yuchong Zhao et al. Cancer Cell International
- FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
- (2021) Erica C. Nakajima et al. CLINICAL CANCER RESEARCH
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- (2021) Yulei Zhao et al. NATURE
- Resistance looms for KRASG12C inhibitors
- (2020) Aaron N. Hata et al. NATURE MEDICINE
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- Global Burden of 5 Major Types Of Gastrointestinal Cancer
- (2020) Melina Arnold et al. GASTROENTEROLOGY
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- An open-source drug discovery platform enables ultra-large virtual screens
- (2020) Christoph Gorgulla et al. NATURE
- Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma
- (2020) Caitlin A. McIntyre et al. CANCER
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Author Correction: RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
- (2019) Hengyu Lu et al. MOLECULAR CANCER THERAPEUTICS
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
- (2019) Isabel Boned del Río et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic targeting of RAS: New hope for drugging the “undruggable”
- (2019) Imran Khan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2019) Avnish Kapoor et al. CELL
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
- (2019) Dana Rabara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
- (2019) Kelvin K. W. Chan et al. Cancer Medicine
- The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2019) Akram Pourshams et al. Lancet Gastroenterology & Hepatology
- KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
- (2018) Chiara Ambrogio et al. CELL
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
- (2018) Xiaoyu Guo et al. Oncotarget
- Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection
- (2018) Lianhua Dong et al. Scientific Reports
- Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study
- (2018) Lei Huang et al. BMC Medicine
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Current Approaches to Pancreatic Cancer Screening
- (2018) Ankit Chhoda et al. AMERICAN JOURNAL OF PATHOLOGY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Survival of pancreatic cancer cells lacking KRAS function
- (2017) Mandar Deepak Muzumdar et al. Nature Communications
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
- (2017) Diána Brauswetter et al. PLoS One
- More deaths from pancreatic cancer than breast cancer in the EU by 2017
- (2016) J. Ferlay et al. ACTA ONCOLOGICA
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review
- (2016) Lei Zhou et al. MEDICAL ONCOLOGY
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
- (2016) Jimi Kim et al. NATURE
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Small Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK Signaling
- (2016) Na Guo et al. PLoS One
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Rational design of protein–protein interaction inhibitors
- (2015) Didier Rognan MedChemComm
- Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
- (2015) Severa Bunda et al. Nature Communications
- Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
- (2015) E. Gabriela Chiorean et al. Drug Design Development and Therapy
- A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
- (2015) Irene Ischenko et al. Oncotarget
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
- (2014) Ming-Tseh Lin et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Total Laparoscopic Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma
- (2014) Kristopher P. Croome et al. ANNALS OF SURGERY
- FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
- (2014) L. Marthey et al. ANNALS OF SURGICAL ONCOLOGY
- KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
- (2014) Diane D. Shao et al. CELL
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Screening for Testicular Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement
- (2013) ANNALS OF INTERNAL MEDICINE
- MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
- (2013) A. R. Chakraborty et al. BLOOD
- Selective Induction of Apoptosis: Promising Therapy in Pancreatic Cancer
- (2013) Zuojia Liu et al. CURRENT PHARMACEUTICAL DESIGN
- Rational Drug Design: The Search for Ras Protein Hydrolysis Intermediate Conformation Inhibitors with Both Affinity and Specificity
- (2013) Xiliang Zheng et al. CURRENT PHARMACEUTICAL DESIGN
- A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells
- (2013) Dan Li et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Spiclomazine Induces Apoptosis Associated with the Suppression of Cell Viability, Migration and Invasion in Pancreatic Carcinoma Cells
- (2013) Wenjing Zhao et al. PLoS One
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- A Potent Lead Induces Apoptosis in Pancreatic Cancer Cells
- (2012) Zuojia Liu et al. PLoS One
- Can Laparoscopic Pancreaticoduodenectomy Be Safely Implemented?
- (2011) Amer H. Zureikat et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Carboxyalkyl peptoid PNAs: synthesis and hybridization properties
- (2011) Chiara De Cola et al. TETRAHEDRON
- Total Laparoscopic Pancreaticoduodenectomy
- (2010) Michael L. Kendrick et al. ARCHIVES OF SURGERY
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blockade of the ERK or PI3K–Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib
- (2009) Kei-ichi Ozaki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells
- (2009) E. P. Jane et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
- (2009) Junichi Soh et al. PLoS One
- P120-Ras GTPase activating protein (RasGAP): A multi-interacting protein in downstream signaling
- (2008) Perayot Pamonsinlapatham et al. BIOCHIMIE
- PI3K/Akt: getting it right matters
- (2008) T F Franke ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search